# CD30

5 EU-approved indications of 1 drug need a CD30 result, in 2 tumour types, most of them in hodgkin lymphoma and T-cell lymphoma.

## Approved indications by tumour

### Hodgkin lymphoma

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | CD30 CD30+ | + doxorubicin, vinblastine and dacarbazine | 1st line, advanced | - |
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | CD30 CD30+ | + etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone | 1st line, advanced | Stage IIB with risk factors, Stage III or Stage IV |
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | CD30 CD30+ | Monotherapy | Consolidation | Following autologous stem cell transplant (ASCT); At increased risk of relapse or progression Ambiguous in the label (treatment phase): check the SmPC. |
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | CD30 CD30+ | Monotherapy | 3rd line+ | Following ASCT, or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option |

### T-cell lymphoma

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | CD30 CD30+ | Monotherapy | 2nd line | Cutaneous T-cell lymphoma only; After at least 1 prior systemic therapy |

## Label wording

- **Brentuximab vedotin** (Adcetris), Hodgkin lymphoma, 1st line, advanced: “ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage III or IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) (see sections 4.2 and 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)
- **Brentuximab vedotin** (Adcetris), Hodgkin lymphoma, 1st line, advanced: “ADCETRIS is indicated for adult patients with previously untreated CD30+ Stage IIB with risk factors, Stage III or Stage IV HL in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD) (see sections 4.2 and 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)
- **Brentuximab vedotin** (Adcetris), Hodgkin lymphoma, consolidation: “ADCETRIS is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT) (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)
- **Brentuximab vedotin** (Adcetris), Hodgkin lymphoma, 3rd line+: “ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):
1. following ASCT, or 2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)
- **Brentuximab vedotin** (Adcetris), T-cell lymphoma, 2nd line: “ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/biomarkers/cd30